Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Type 3 hyperlipoproteinaemia.

P Borrie

    British Medical Journal
    |June 14, 1969
    PubMed
    Summary

    Type III hyperlipoproteinaemia patients showed a slightly increased risk of coronary artery disease, but no increased carbohydrate intolerance. Treatment effectively improved skin lesions associated with this lipid disorder.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Letter: Has anyone seen Betty?

    Lancet (London, England)·1974
    Same author

    A clinical syndrome characteristic of primary Type IV-V hyperlipoproteinaemia.

    The British journal of dermatology·1974
    Same author

    Cutaneous polyarteritis nodosa.

    The British journal of dermatology·1972
    Same author

    Cutaneous vasculitis.

    Proceedings of the Royal Society of Medicine·1970
    Same author

    Buzzer ulcers.

    British medical journal·1966
    Same author

    Megaloblastic anaemia during methotrexate treatment of psoriasis.

    British medical journal·1966

    Area of Science:

    • Lipidology
    • Cardiovascular Medicine
    • Genetics

    Background:

    • Type III hyperlipoproteinaemia is a rare genetic lipid disorder.
    • Characterized by abnormal lipoprotein metabolism and characteristic skin lesions.
    • Associated with increased risk of atherosclerosis.

    Purpose of the Study:

    • To investigate the long-term clinical outcomes in patients with type III hyperlipoproteinaemia.
    • To assess the incidence of cardiovascular disease and carbohydrate intolerance.
    • To evaluate the efficacy of treatment on skin manifestations.

    Main Methods:

    • Longitudinal study of 18 patients diagnosed with type III hyperlipoproteinaemia.
    • Inclusion criteria: skin lesions, serum lipids, and lipoprotein electrophoresis.
    • Data collection over a 15-year period, including family history.

    Main Results:

    • Slightly increased incidence of coronary artery disease in patients.
    • No increased incidence of carbohydrate intolerance in patients or relatives.
    • Peripheral occlusive arterial disease was potentially more common.
    • Treatment demonstrated uniformly good effects on skin lesions.

    Conclusions:

    • Type III hyperlipoproteinaemia carries a modest risk for coronary artery disease.
    • Carbohydrate intolerance is not a significant comorbidity in this condition.
    • Therapeutic interventions are effective for managing the cutaneous manifestations.

    Related Experiment Videos